Table 5.

Overview of other therapies for SCA 1.

	Treatment	Animal model	Route	Outcome
Cvetanovic et al., 2011	VEGF	154Q/2Q mice	Pharmacologic: intraventricular infusion	Improved pathological hallmarks and motor function
			Transgenic: gene over-expression
Hearst et al., 2014a	PKA inhibitory polypeptide (Synb1-ELP-PK)	B05 mice	Intraperitoneal/intranasal	Decreased intranucelar inclusions, improved PC morphology
Hourez et al., 2011	3,4-diaminopyridine	B05 mice	Subcutaneous injection	Normalized PC firing rate, reduced PC atrophy, improved motor function
Hearst et al., 2014b	Focused Laser Light Hyperthermia	B05 mice	Cerebellar	Hsp70 production, suppressed PC loss, improved motor function
Watase et al., 2002	Lithium	154Q/2Q	Dietary	Improved motor coordination, learning, and memory. Increased Dendritic branching in hippocampal pyramidal neurons
Perroud et al., 2013	Lithium	154/2Q	Dietary	Increased metabolic processes, specifically higher purine levels
Iizuka et al., 2015	Memantine	154Q/2Q	Dietary	Attenuated PC loss and vagus motor neuron loss. Extended life span and reduced weight loss